Reviews are good from Germanybut none newer than 6 months which raises the question of whether we are availble, sold out, consumers loss of interest or other problems related to supply and sales.
More questions than answers and low volume suggests low interest in our sku from consumers and the shareprice suggests low interest from investors.
Long lasting malaise in cannabinoid investments and the possibility that this is hanging by a thread with no catalyst forthcoming by politicians in the US.
Nothing from our management team to suggest any kind of a plan or even solvency is concerning.
Sadly we have to face the possibility of self interested management with a deliberative plan to wind up with the spoils or that they just don't have an alternative plan.
I kind of think that Cryopharm was our inspiration but I am not sure of their viability and they are not publicly traded that I am aware of.
We could be in that 90% plus pot cos destined for failure and delisting, sadly after 10 years survival.
glta and dyodd